Press release
HDAC Inhibitors Market, by Application, End User, and Geography – Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2025
Regional segmentation of HDAC inhibitors market by Coherent Market Insights, includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the market due to growing incidence of cancer and rising demand for cancer therapeutics in the region. According to American Cancer Society, in 2017, 1,688,780 new cancer cases and 600,920 deaths due to cancer are estimated to occur in the U.S. Better funding for R&D for cancer treatment, and growing demand for efficient treatment with lower costs are other factors driving growth of the market. In 2017, Congress approved the 21st Century Cures Act, sanctioning US$ 1.8 billion in aid for the Cancer Moonshot initiative for 7 years. Europe is expected to foresee tremendous growth during the forecast period (2017–2025), due to growing presence of well-established healthcare infrastructure, early adoption of innovative therapeutics, and growing R&D spending capacity.Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/1294
Major players operating in the HDAC inhibitors market include AbbVie, Celgene, Celldex, Chipscreen, Chroma Therapeutics, GSK, Merck, Novartis, Onxeo, Syndax, and Spectrum Pharmaceuticals. Various pharmaceutical firms are increasingly investing in R&D and preclinical activities of HDACi for different applications. In January 2018, Syndax and Genentech extended their study of the effects of combining PD-L1 and HDAC inhibitors. This new contract permits Genentech to test its Tecentriq with Syndax’s entinostat in a subset of breast cancer patients.
In February 2015, Novartis received the U.S. FDA approval for Farydak capsules along with dexamethasone and bortezomib*, for patients suffering from multiple myeloma, who previously received minimum two regimens. FDA approval of few HDAC inhibitors for cancer treatment has created interest in finding new products as potential anti-cancer drugs. Moreover, increasing R&D activities for the treatment of cancer and other neurological disorders is one of the prime factors responsible for growth of the HDAC inhibitors market. Around 350 clinical trials were carried out or under process using HDACi as single therapeutic or along with other targeted agents against different human diseases. However, uncertainty issues about the therapeutic potential of HDAC inhibitors and stringent reimbursement policies is expected to impede growth of the market in near future. For instance, there can be significant delays in gaining reimbursement and coverage for newly approved drugs by FDA or other foreign regulatory authorities.
Numerous classes of Histone deacetylase inhibitors, include benzamides such as MS-275, organic hydroxamic acids such as TSA and SAHA, cyclic tetrapeptides such as sulfonamide anilides and trapoxin, and short-chain fatty acids such as valproic acid and butyrates. Increasing number of applications in different therapeutic areas such as neurodegenerative diseases, including Huntington’s and Alzheimer’s disease, Polycythemia vera, inflammation, and essential Thrombocythemia, Myelofibrosis, is expected to fuel the demand for HDAC inhibitors in the near future.
To get holistic SAMPLE with TOC @ https://www.coherentmarketinsights.com/ongoing-insight/toc/1294
HDAC inhibitors refers to the class of anti-cancer agents that play a vital role in non-epigenetic or epigenetic regulation, inducing cell cycle arrest, apoptosis, and death of cancer cells. Histone deacetylase inhibitors (HDACi) are promising therapeutics, which have already shown potential for oncological applications such as cancer detection, diagnosis, and prognosis. For instance, Vorinostat (Merck & Co. Inc.) is a novel drug used in the management of cutaneous T cell lymphoma during disease progression or relapse or while undergoing treatment. Current candidates are demonstrating successful pre-clinical and clinical trials for various other diseases such as neurological ailments, heart diseases, and HIV infections.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
1001 4th Ave,, #3200, Seattle, WA 98154
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release HDAC Inhibitors Market, by Application, End User, and Geography – Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2025 here
News-ID: 1032263 • Views: …
More Releases from CMI Research Report

Hospital Beds Market worth US$ 5.2 Billion by 2025 Globally
Many of the hospitals have shifted their capital funds towards the hospital infrastructure, which is mainly seen in private hospitals. Improving healthcare amenities along with increasing spending in healthcare is expected to boost growth of hospitals beds market globally. Increasing number of geriatric population and need for their treatment is expected to fuel the growth of hospital bed market over the forecast period. The number of hospital beds are very…

Acute Bacterial Skin and Skin Structure Infections Market Sales, Size, Leading P …
Acute Bacterial Skin and Skin Structure Infections (ABSSSI) are the type of skin and soft tissue infections that affects the epidermis, dermis, and subcutaneous tissues. The US FDA defines ABSSSI as lesions with cellulitis/erysipelas, wound infections, and major cutaneous abscesses occurring in a minimum surface area of 75 cm2. Pathogens such as Methicillin sensitive Staphylococcus aureus (MSSA), Methicillin resistant Staphylococcus aureus (MRSA), Beta-hemolytic Streptococcus, Escherichia coli, Enterococcus faecalis, and Pseudomonas…

Adrenocortical Carcinoma Treatment Market 2017 Industry Analysis, Segment & Fore …
Adrenocortical carcinoma is a rare cancer affecting the outer layer of the adrenal glands, which are responsible for producing certain hormones and maintaining optimum blood pressure levels. Adrenocortical carcinoma is relatively frequent in children compared to other cancers, although the cancer may also affect adults. The most common symptoms of adrenocortical carcinoma include abdominal pain, hypertension, weight gain, and frequent urination, which are mainly caused due to tumors causing excess…

Primary Biliary Cirrhosis Drugs Market Overview, Trends and Growth Opportunities …
Primary biliary cirrhosis, known as primary biliary cholangitis is a chronic liver disease, which causes liver inflammation, fibrosis, and obstruction in the bile duct leading to destruction of small bile ducts within liver. Cause for primary biliary cirrhosis can be autoimmunity, infection and/or genetic predisposition. Symptoms of primary biliary cirrhosis includes itching, osteoporosis, elevated serum cholesterol, and malabsorption of fat and fat soluble vitamins, which can advance to hepatomegaly, hyperpigmentation,…
More Releases for HDAC
Rising Neurodegenerative Disorders Drive Growth In HDAC Inhibitors Market: Pivot …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Histone Deacetylase (HDAC) Inhibitors Market Size Growth Forecast: What to Expect by 2025?
The market for histone deacetylase (HDAC) inhibitors has seen substantial growth in the last few years. The market is predicted to expand from a size of $1.23 billion in 2024 to $1.33 billion in 2025, with…
HDAC Inhibitors Market Projected to Grow Significantly Through 2034 | DelveInsig …
The HDAC Inhibitors companies in the market include - Merck & Co., Bristol Myers Squibb, Celgene Corporation, Spectrum Pharmaceuticals, and Syndax Pharmaceuticals, among others.
The HDAC inhibitor market has shown significant growth in recent years, driven by the increasing prevalence of several key indications commonly treated with HDAC inhibitors, growing research in epigenetics, and expanding applications beyond oncology. According to DelveInsight's comprehensive analysis, key pharmaceutical companies, including Merck & Co., Bristol…
Key Trend Reshaping the Histone Deacetylase (HDAC) Inhibitors Market in 2025: Sh …
Which drivers are expected to have the greatest impact on the over the histone deacetylase (hdac) inhibitors market's growth?
The increasing incidence of neurodegenerative diseases is expected to drive the growth of the histone deacetylase (HDAC) inhibitors market. Neurodegenerative disorders, such as Alzheimer's disease, involve the progressive degeneration of neurons, leading to cognitive and motor dysfunction. The rising prevalence of these disorders is due to aging, genetics, and environmental factors. HDAC…
HDAC Inhibitor Treatment Drugs, Clinical Trials, Pipeline Insights, and Companie …
DelveInsight's, "HDAC Inhibitor Pipeline Insight 2024" report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in HDAC Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our comprehensive HDAC Inhibitor Pipeline Report to stay informed about…
Histone Deacetylase (HDAC) Inhibitors Market 2022 | Detailed Report
The Histone Deacetylase (HDAC) Inhibitors research report undoubtedly meets the strategic and specific needs of the businesses and companies. The report acts as a perfect window that provides an explanation of market classification, market definition, applications, market trends, and engagement. The competitive landscape is studied here in terms of product range, strategies, and prospects of the market's key players. Furthermore, the report offers insightful market data and information about the…
HDAC Inhibitors Market - Increasing R&D activities for cancer is expected to boo …
Overview
HDAC inhibitors are a kind of anti-cancer drug that works by causing cell cycle arrest, apoptosis, and death in cancer cells through non-epigenetic or epigenetic control. HDAC inhibitors (HDACi) are potential medicines that have already demonstrated promise in oncological applications such as cancer detection, treatment, and prognostic. Vorinostat (Merck & Co. Inc.) is a new medication that is used to treat epidermal T cell lymphoma as it progresses, relapses, or…